Skip to main content
. 2017 Apr 10;8(35):59878–59888. doi: 10.18632/oncotarget.17001

Table 1. Characteristics of included studies.

First author Year Region Sample Measure method Age (years) N. of M/F Primary antibody Treatment Follow-up
Bian 2015 China Tissue IHC NR NR Rabbit Ab Surgery Median 49 months
(2-80months)
Chang 2015 Korea Tissue IHC Mean 58.1 285/139 Rabbit pAb Surgery Mean 82.3 months;
Median 61 Median96.1months
(1 –131 months)
Cinti 2008 Italy Tissue IHC 34-83years 16/34 mAb Surgery at least 5 years
Han 2011 China Tissue IHC Median 53 85/23 Rabbit pAb Surgery About 5 years
Chemotherapy
Kobayashia 2006 Japan Tissue IHC NR NR Rabbit pAb Surgery >40 months
Liang 2015 China Tissue IHC NR NR mAb Surgery >5 years
Luber 2011 Europe Tissue IHC Median 63 30/9 Mouse mAb Chemotherapy Median 379 days
Murakami 2007 Japan Tissue IHC Mean 70.8 84/56 Mouse pAb Surgery at least 5 years
Chemotherapy
Murayama 2009 Japan Tissue IHC Median 65 77/32 Rabbit pAb Surgery Median 1953 days
(50– 3197 days)
Nam 2003 Korea Tissue IHC Mean 54.8 210/101 NR Surgery Mean 54 months
(1-72 months)
Sasaki 2014 Japan Tissue Immunoblot NR NR NR Surgery >5 years
Sukawa 2012 Japan Tissue IHC Median 71 157/74 pAb Surgery About 10 years
Xue 2012 China Tissue IHC Median65.5 158/71 Mouse pAb Surgery >5 years

N. of P.: the number of patients; M/F: male/female; mAb: monoclonal antibody; pAb: polyclonal antibody; NR: not reported.